List of Onureg drug patents

Onureg is owned by Celgene Corp.

Onureg contains Azacitidine.

Onureg has a total of 1 drug patent out of which 0 drug patents have expired.

Onureg was authorised for market use on 01 September, 2020.

Onureg is available in tablet;oral dosage forms.

Onureg can be used as continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy.

The generics of Onureg are possible to be released after 03 June, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846628 CELGENE CORP Oral formulations of cytidine analogs and methods of use thereof
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 1, 2023
Orphan Drug Exclusivity (ODE) Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy

Dosage: TABLET;ORAL

How can I launch a generic of ONUREG before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in